XenoPort accuses GSK of contract breach, failing to maximise sales of Horizant
This article was originally published in Scrip
Executive Summary
XenoPort said it has delivered a breach of contract notice to GlaxoSmithKline, its commercial partner, alleging GSK has not met its obligation to maximise the US sales of their product, Horizant (gabapentin encarbil) extended-release tablets for restless legs syndrome (RLS), according to a 25 January regulatory filing. GSK has 90 days to address the issues raised.